PDT Partners’s Cue Biopharma CUE Stock Holding History

PDT Partners’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-839	Closed	-$123K	–	994
2022 Q1	$123K	Buy	+839	New	+$178K	0.01%	854
2021 Q1	–	Sell	-412	Closed	-$155K	–	794
2020 Q4	$155K	Buy	412 +5	+1%	+$2K	0.01%	633
2020 Q3	$184K	Buy	+407	New	+$235K	0.01%	639

Other funds holding CUE

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

PDT Partners's CUE Position: Q2 2022 in Review

PDT Partners sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 839 shares — an estimated $123K sold.

PDT Partners first reported a position in CUE in Q3 2020 and held it in 3 quarters. The position peaked at $184K in Q3 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

PDT Partners reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 839 Cue Biopharma shares in Q2 2022, an estimated $123K.
PDT Partners first reported a position in Cue Biopharma in Q3 2020 and held it in 3 quarters.
PDT Partners's Cue Biopharma position peaked at $184K in Q3 2020.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.